



Unaudited Financial Results
for the quarter ended June 30, 2012

Rs. In Lacs (Except for per share data)

	Quarter ended		Unaudited 30th June 2011	Year ended Audited 31st March 2012
	Unaudited 30th June 2012	Audited 31st March 2012		
Sales / income from operations	16,659	22,310	14,687	70,892
Less: Excise duty	133	175	407	1,469
Net sales / income from operations	16,526	22,135	14,280	69,423
Total expenditure				
a) Cost of materials and utilities consumed	9,638	12,169	7,768	37,128
b) Purchases of stock- in- trade	-	-	-	-
c) Change in inventories of finished goods and work in progress	(829)	1,007	357	1,615
d) Employee benefits expense	1,592	1,347	1,391	5,569
e) Depreciation and amortisation expenses	1,178	1,069	1,026	4,242
f) Other expenses	1,606	2,430	1,454	8,396
Total expenditure	13,185	18,022	11,996	56,950
Profit from operations before other income, interest and impact of forward contracts	3,341	4,113	2,284	12,473
Other income	33	150	138	496
Profit before interest and impact of forward contracts	3,374	4,263	2,422	12,969
Finance cost	1,277	1,254	1,127	4,776
Profit from ordinary activities before tax and impact of forward contracts	2,097	3,009	1,295	8,193
- Exchange loss (Refer note no.3 below)	1,537	1,029	199	2,556
- Reversal of cash flow hedge reserve	-	-	(371)	(371)
Profit from ordinary activities before tax	560	1,980	1,467	6,008
Provision for taxation				
-Current taxes	122	336	293	1,228
-Minimum Alternative Tax credit	(122)	(336)	(293)	(1,228)
-Deferred tax	50	469	17	599
Net profit after tax	510	1,511	1,450	5,408
Paid-up equity share capital	1,644	1,644	1,644	1,644
Reserves excluding revaluation reserves				33,474
Earnings per share (face value Rs.10/-)				
- Basic	3.10	9.19	8.82	32.90
- Diluted	3.10	9.19	8.82	32.90
- Cash	10.27	15.69	15.06	58.70
A. PARTICULARS OF HOLDINGS				
Public shareholding				
- No of shares	5,125,963	5,125,963	5,125,363	5,125,963
- Percentage of shareholding	31.18%	31.18%	31.18%	31.18%
Promoters and promoter group shareholding				
a) Pledged / Encumbered				
- No of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	-	-	-	-
- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
b) Non-encumbered				
- No of shares	11,314,137	11,314,137	11,314,737	11,314,137
- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	68.82%	68.82%	68.82%	68.82%

B. INVESTOR COMPLAINTS

	June 30, 2012
Pending at the beginning of the quarter	Nil
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	Nil

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on August 9, 2012
2. The Scheme of Arrangement for merger of Acoris Research Limited (ARL) with the Company was sanctioned by Hon'ble High Court of Bombay vide its order dated March 30, 2012. Accordingly, ARL was merged with the Company from the Appointed Date April 1, 2012. Accordingly, effective April 1, 2012 all assets/liabilities of ARL is taken over by the company at the book value and the difference of Rs.2,850 lacs between the assets/liabilities is adjusted in Securities Premium Account. In view of the aforesaid merger, the figures for the current quarter including EPS are strictly not comparable with those of the corresponding period of the previous year.
3. The Company has entered into forward/options contracts to hedge its exposure to fluctuations in foreign exchange for approx 30% of future exports. These covers have been staggered upto the period March 31, 2013, as the major percentage of the Company's turnover is realized from exports. The Company is of the opinion that the result of these transactions represent unrealised losses that are notional in nature. The management is of the opinion that the fluctuation in currency movements against hedged contracts gets compensated by realization of a higher value of sales realizations and therefore, the actual profit/loss against such outstanding contracts crystallizes only on maturity of such forward contracts. The gain/ loss on these transactions will be recognised as and when they fall due. The mark to market valuation loss is Rs. 4,673 lacs as on June 30, 2012 (corresponding previous period as on June 30, 2011 Rs.2,550 lacs). Further, due to extant volatility in foreign currency rates the exchange difference of Rs. 750 lacs as on June 30, 2012 on outstanding short term working capital loans, will be accounted at the rate prevailing on the date of payment.
4. The results for the quarter ended June 30, 2012 have been subjected to a "Limited Review" by the Statutory Auditors of the Company. The limited review report has been modified with respect to note no.3 above. The limited review report will be filed with the stock exchanges and will be available on the Company's web site - www.hikal.com.
5. The figures for the three months ended March 31, 2012 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Place : Mumbai
Date : August 9, 2012

For HIKAL LTD



Jai Hiremath
Chairman &
Managing Director

HIKAL LTD

Regd. Office : 717/718, Maker Chamber V, Nariman Point, Mumbai - 400 021.

Just the right chemistry



Segment wise revenue , results and capital employed as on June 30, 2012

	Rs. In lacs			
	Unaudited 30th June 2012	Quarter ended Audited 31st March 2012	Unaudited 30th June 2011	Year Ended Audited 31st March 2012
1. Segment Revenue				
a) Pharmaceuticals	9,595	13,529	9,497	44,769
b) Crop protection products	6,931	8,606	4,783	24,654
Total	16,526	22,135	14,280	69,423
Less: Inter segment revenue	-	-	-	-
Net sales/income from operations	16,526	22,135	14,280	69,423
2. Segment Results				
Profit before interest and tax				
a) Pharmaceuticals	2,515	3,755	2,583	12,405
b) Crop protection products	1,316	1,186	375	2,734
Total	3,831	4,941	2,958	15,139
Less :				
i) Interest	1,277	1,254	1,127	4,776
ii) Other un-allocable expenditure net off un-allocable income	1,994	1,707	364	4,355
Profit before tax	560	1,980	1,467	6,008
3. Capital employed				
a) Pharmaceuticals	60,909	52,771	48,322	52,771
b) Crop protection products	27,961	27,734	28,254	27,734
c) Unallocated capital	(45,247)	(34,522)	(33,346)	(34,522)
Total	43,623	45,983	43,230	45,983

For HIKAL LTD

Jai Hiremath
Chairman &
Managing Director

Place : Mumbai
Date : August 9, 2012

HIKAL LTD

Regd. Office : 717/718, Maker Chamber V, Nariman Point, Mumbai - 400 021.

Just the right chemistry

B S R & Company

Chartered Accountants

Lodha Excelus
1st Floor, Apollo Mills Compound
N. M. Joshi Marg
Mahalakshmi
Mumbai - 400 011
India

Telephone +91 (22) 3989 6000
Fax +91 (22) 3983 6000

Review report

To the Board of Directors of Hikal Limited

- 1 We have reviewed the accompanying statement of un-audited financial results ('the Statement') of Hikal Limited ('the Company') for the quarter ended 30 June 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. Attention is drawn to the fact that the figures for the three months ended 31 March 2012 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- 2 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3 *As more fully explained in note no. 3 to the Company's statement of un-audited financial results, the Company has not provided for a "mark-to-market" loss on derivative contracts/receivables aggregating to Rs 4,673 lakhs as at 30 June 2012 (30 June 2011: Rs 2,550 lakhs) and for the exchange difference on working capital loans aggregating to Rs 750 lakhs as at 30 June 2012 (30 June 2011: Rs Nil) for the reasons stated by the management in the said note. Consequently, without considering the tax effect, the profit before tax for the quarter and capital employed are overstated by Rs 5,423 lakhs (30 June 2011: Rs 2,550 lakhs).*
- 4 Based on our review conducted as above, *subject to our comments in paragraph 3 above*, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with the accounting standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Company**
Chartered Accountants
Firm's Registration No: 128032W



Vijay Bhatt
Partner

Membership No: 036647

Mumbai
9 August 2012